Variety of eligible clients: CDEC mentioned the uncertainty in the quantity of people with moderately intense to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some clients who're categorized as obtaining gentle or average condition can have a serious bleeding phenotype, w